Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 14/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | IARS1 | P41252 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324435 | 1.00 | ALDH1A1 (0.50) | ALDH1A1DPP4DPP8DPP9DPP7 | |
| SCHEMBL542821 | 0.92 | DPP4 (0.41) | ALDH1A1DPP4DPP8DPP9DPP7 | |
| SCHEMBL3283798 | 0.88 | MAPT (0.47) | ALDH1A1 | |
| SCHEMBL598924 | 0.88 | MAPT (0.47) | ALDH1A1 | |
| SCHEMBL6136549 | 0.86 | DPP4 (0.42) | DPP4DPP8DPP9DPP7IARS1 | |
| SCHEMBL599360 | 0.86 | LMNA (0.50) | ALDH1A1 | |
| SCHEMBL598488 | 0.86 | LMNA (0.50) | ALDH1A1 | |
| SCHEMBL598288 | 0.86 | LMNA (0.50) | ALDH1A1 | |
| SCHEMBL9664746 | 0.86 | LMNA (0.50) | ALDH1A1 | |
| SCHEMBL9665651 | 0.86 | LMNA (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946499-B1 | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-06-01 | — | — | EP | claimed |
| EP-1948199-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LAB INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-9078864-B2 | Agonists for antimicrobial peptide systems | AKTHELIA PHARMACEUTICALS (IS) | 2015-07-14 | — | — | US | disclosed |
| EP-1960415-B1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LAB INC (US) | 2015-03-04 | — | — | EP | disclosed |
| CN-101959429-B | Agonists of antimicrobial peptide systems | AKTHELIA PHARMACEUTICALS | 2014-09-10 | — | — | CN | disclosed |
| US-8293253-B2 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8114440-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8017159-B2 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110118217-A1 | Agonists for Antimicrobial Peptide Systems | AKTHELIA PHARMACEUTICALS (IS) | 2011-05-19 | — | — | US | disclosed |
| CN-101959429-A | Agonists of antimicrobial peptide systems | AKTHELIA PHARMACEUTICALS | 2011-01-26 | — | — | CN | disclosed |
| WO-2007058800-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058801-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2006050002-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. | 2006-05-04 | — | — | US | disclosed |
| EP-0946499-B1 | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030109582-A1 | Methods and compositions for stimulating secretions from paneth cells | INNATE IMMUNITY, INC. | 2003-06-12 | — | — | US | disclosed |
| US-20020131996-A1 | Methods and compositions for blocking microbial adherence to eukaryotic cells | ACTUA THERAPEUTICS, LLC | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | LIPA, CEL, LPXN | ALDH1A1 1640/4885DPP4 497/4885DPP8 608/4885 |
| US-20110118217-A1 | Agonists for Antimicrobial Peptide Systems | VIP, GLP1R, MAVS | ALDH1A1 3865/4885DPP4 72/4885DPP8 161/4885 |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | ALDH1A1 4408/4885DPP4 1254/4885DPP8 1104/4885 |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | ALDH1A1 4408/4885DPP4 1254/4885DPP8 1104/4885 |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | ANXA6, ANXA2, PLTP | ALDH1A1 3745/4885DPP4 2561/4885DPP8 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.